Palo Alto, California 94305

  • Melanoma, Skin


The purpose of this study is to determine the signaling pathways and changes in gene expression in melanocytes of subjects with a history of non-melanoma skin cancer who are exposed to oral vitamin D. If vitamin D is found to inhibit a signaling pathway involved in the development of melanoma such as BRAF, a protein involved in cell proliferation, then oral vitamin D could be explored further as a chemoprevention for melanoma skin cancer.


Inclusion Criteria: 1. Age 18 - 75 2. Female 3. White race/ethnicity 4. With history of non-melanoma skin cancer 5. Has 12-16 moles upon skin examination 6. Consents to 6-12 moles biopsies over 2-3 clinic visits (2-4 months) 7. Consents to ingesting oral vitamin D3 or placebo daily for 2-4 months 8. Consents to abstaining from other multivitamins during study 9. Consents to research use of their tissue and blood samples 10. Agrees to apply a sunscreen of SPF 45 during study - Exclusion Criteria: 1. History or current evidence of hyperparathyroidism, hypercalcemia, renal calculi, or other renal disease. 2. History or current evidence of malabsorptive illnesses, such as IBD, or liver disease that would impair uptake or metabolism of vitamin D. 3. History or current evidence of hyperthyroidism that would increase metabolism of vitamin D. 4. History or current evidence of immunosuppression (cancer, autoimmune disease) or taking immunosuppressive drugs. 5. Currently taking medications that would affect metabolism of vitamin D (anticonvulsants, corticosteroids, H2-receptor antagonists). 6. Currently taking medications that predispose to hypercalcemia (digoxin, lithium, thiazide diuretics) or other electrolyte disturbances (aluminum hydroxide) 7. Pregnancy



Primary Contact:

Principal Investigator
Jean Yuh Tang, MD, PhD
Stanford University

Irene Bailey
Phone: 650-721-7149

Backup Contact:


Location Contact:

Palo Alto, California 94305
United States

Irene Bailey
Phone: 650-498-7061

Site Status: Recruiting

Data Source:

Date Processed: September 16, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.